anti-TL1A fusion protein

Anti-TL1A fusion proteins are a class of therapeutic biologics designed to neutralize Tumor Necrosis Factor-like Ligand 1A (TL1A), a cytokine belonging to the TNF superfamily (TNFSF15). TL1A plays a critical role in modulating immune responses by binding to its primary signaling receptor, Death Receptor 3 (DR3), which is expressed on T cells, NK cells, and innate lymphoid cells. Overexpression of TL1A is strongly associated with the pathogenesis of inflammatory bowel diseases (IBD), including Ulcerative Colitis and Crohn's Disease, where it promotes Th1 and Th17 effector cell function and drives fibrostenosis. Fusion protein modalities in this space typically utilize a decoy receptor approach, such as a DcR3-Fc fusion, which mimics the naturally occurring decoy receptor 3 (DcR3) to sequester soluble TL1A and prevent its interaction with DR3. While several monoclonal antibodies targeting TL1A (e.g., tulgisbart, tulisokibart) have reached advanced clinical stages, fusion protein architectures represent an alternative strategy to modulate this pathway for autoimmune and fibrotic indications.

Other names

anti-TL1A fusion proteinanti-TL-1A fusion proteinanti-TL 1A fusion proteinTL1A fusion proteinTL-1A fusion proteinTL 1A fusion proteinTL1A decoy receptor fusion proteinTL-1A decoy receptor fusion proteinTL 1A decoy receptor fusion proteinDcR3-Fc fusion proteinDcR-3-Fc fusion proteinDcR 3-Fc fusion protein